Abbott, AbbVie and Novartis side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Abbott | AbbVie | Novartis |
|---|---|---|---|
| Phase 1 | – | AbbVie: 28 of its 70 programs at phase 1
and 23 more — sign in to see them all | Novartis: 16 of its 77 programs at phase 1
and 11 more — sign in to see them all |
| Phase 2 | – | AbbVie: 20 of its 70 programs at phase 2
and 15 more — sign in to see them all | Novartis: 35 of its 77 programs at phase 2
and 30 more — sign in to see them all |
| Phase 3 | – | AbbVie: 16 of its 70 programs at phase 3
and 11 more — sign in to see them all | Novartis: 18 of its 77 programs at phase 3
and 13 more — sign in to see them all |
| Approved, new studies | – | AbbVie: 6 of its 70 programs at approved, new studies
and 1 more — sign in to see them all | Novartis: 8 of its 77 programs at approved, new studies
and 3 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
| AbbVie34 readouts · 5 phase 3 | AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3
and 1 more — sign in to see them all | AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3
| AbbVie, Jan ’27: 1 program whose next study reaches primary completion
| AbbVie, Feb ’27: 9 programs whose next study reaches primary completion
and 4 more — sign in to see them all | · | AbbVie, Apr ’27: 1 program whose next study reaches primary completion
| AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3
and 1 more — sign in to see them all | AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| AbbVie, Jul ’27: 4 programs whose next study reaches primary completion
| AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| AbbVie, Sep ’27: 1 program whose next study reaches primary completion
| · |
| Novartis27 readouts · 5 phase 3 | Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Novartis, Dec ’26: 5 programs whose next study reaches primary completion
| Novartis, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Apr ’27: 4 programs whose next study reaches primary completion
| Novartis, May ’27: 2 programs whose next study reaches primary completion
| · | Novartis, Jul ’27: 3 programs whose next study reaches primary completion
| Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Novartis, Sep ’27: 1 program whose next study reaches primary completion
| · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Abbott
No programs read for this company.
AbbVie
New programs 5
- [11C]ABBV-112iearly phase 1 · first study · Nov 6
- ABBV-7828phase 1 · first study · Sep 28
- ABBV-1162phase 1 · first study · Sep 16
- ABBV-253phase 1 · first study · Sep 1 · Carcinoma, Non-Small-Cell Lung
- NOA LIFTphase 3 · first study · Aug 27
Reached a new phase 1
- ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic
Study stopped 0
None
Primary completion later 10
- upadacitinibphase 3 · Mar 2028 → Aug 2028 (+5 mo) · moved Nov 13 · NCT05889182
- ABBV-547phase 2 · Dec 2027 → Aug 2029 (+20 mo) · moved Nov 9 · NCT06865105
- ABBV-701phase 2 · Dec 2027 → Aug 2029 (+20 mo) · moved Nov 9 · NCT06865105
- lutikizumabphase 2 · Dec 2027 → Aug 2029 (+20 mo) · moved Nov 9 · NCT06865105
- risankizumabphase 2 · Dec 2027 → Aug 2029 (+20 mo) · moved Nov 9 · NCT06865105
- etentamigphase 3 · Sep 2040 → Mar 2041 (+6 mo) · moved Oct 19 · NCT07095452
+4 more
- upadacitinibphase 3 · Jun 2027 → Jan 2031 (+43 mo) · moved Oct 16 · NCT06332534
- upadacitinibphase 3 · Aug 2026 → Nov 2026 (+3 mo) · moved Oct 16 · NCT06389136
- ABBV-547phase 1 · Aug 2027 → May 2028 (+9 mo) · moved Oct 15 · NCT07232004
- telisotuzumab adizutecanphase 3 · Dec 2031 → Nov 2036 (+59 mo) · moved Oct 5 · NCT07005102
Novartis
New programs 5
- pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
- DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
- TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
- XEP527phase 1 · first study · Oct 26 · Schizophrenia
- YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease
Reached a new phase 1
- Oligonucleotides, Antisensephase 2 · Oct 5 · Supranuclear Palsy, Progressive
Study stopped 5
- Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
- pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
- opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
- ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
- pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306
Primary completion later 5
- pelabresibphase 3 · Jun 2027 → Dec 2029 (+31 mo) · moved Nov 12 · NCT06401356
- inclisiranapproved, new study · Feb 2027 → Feb 2028 (+12 mo) · moved Oct 30 · NCT07684469
- pelacarsenphase 3 · Dec 2028 → Jan 2029 (+2 mo) · moved Oct 14 · NCT07625306
- Alpelisibphase 2 · Aug 2028 → Jan 2029 (+6 mo) · moved Oct 5 · NCT06997588
- ianalumabphase 3 · Apr 2030 → Apr 2034 (+48 mo) · moved Oct 1 · NCT06133972
Where they overlap
Conditions where at least two of them have programs: 28 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (AbbVie: 8, Novartis: 7).